Addyi Cost in Michigan 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Flibanserin and Why Does Michigan Pricing Matter?

Flibanserin, sold under the brand name Addyi, is the first FDA-approved oral treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The drug acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, distinguishing it from hormonal therapies used for postmenopausal sexual dysfunction [2]. Because the drug carries a Risk Evaluation and Mitigation Strategy (REMS) program requiring both prescriber certification and dispensing-pharmacy certification, access pathways differ from a standard oral tablet, and that complexity shapes pricing across every state, including Michigan [1].

Michigan has roughly 10 million residents, and population surveys suggest approximately 10% of premenopausal women meet diagnostic criteria for HSDD at any given time [3]. That translates to a substantial patient population who need clear, accurate cost information before starting treatment. Prices at the pharmacy counter vary depending on insurance tier, Medicaid enrollment status, use of manufacturer savings programs, and whether a patient opts for a compounded formulation instead of the brand product.

The sections below walk through each cost pathway available to Michigan patients in 2026, starting with the brand cash price and ending with a practical decision framework for minimizing out-of-pocket spending.

Brand-Name Addyi Cash Price in Michigan in 2026

The Sprout Pharmaceuticals manufacturer list price for Addyi is $880 per month in 2026. That figure represents the wholesale acquisition cost before any rebates, copay cards, or insurance adjustments. At retail Michigan pharmacies, the cash-pay price closely tracks that list price, averaging $880 per 30-tablet supply.

For context, the FDA approved Addyi in August 2015 at a similar price point, and the list price has remained in the $800 to $880 range through successive years [1]. No authorized generic version of flibanserin is currently available in the United States, which means brand-name pricing faces no downward pressure from generic competition. Patients paying entirely out of pocket in Michigan should expect to budget close to $10,560 per year if they remain on the brand product without assistance.

GoodRx and similar discount aggregators occasionally show Michigan pharmacy prices in the $800 to $870 range using discount codes, but these are still far above what most patients consider affordable for a long-term prescription. Savings are modest compared to the list price because no true generic exists to anchor lower tiers.

Michigan Medicaid Coverage for Addyi

Michigan Medicaid covers Addyi with a prior authorization (PA) requirement. Prescribers must submit clinical documentation demonstrating the patient meets diagnostic criteria for HSDD, has a confirmed premenopausal status, and has been assessed for contraindications, including alcohol use and concomitant CYP3A4 inhibitor use [4].

The American College of Obstetricians and Gynecologists (ACOG) defines HSDD in its clinical guidance as "low sexual desire that causes personal distress, is not attributable to a co-existing medical or psychiatric condition, relationship problems, medication effects, or other identifiable cause" [5]. This definition largely mirrors the DSM-5 criteria for Female Sexual Interest/Arousal Disorder (FSIAD), and Michigan Medicaid PA forms typically reference these criteria when evaluating prior authorization submissions.

For patients enrolled in Michigan Medicaid who meet PA requirements, the approved drug is dispensed at a Medicaid-preferred cost share, which for most Michigan Medicaid beneficiaries means minimal to zero copay. Processing a PA typically takes 3 to 10 business days, though urgent PA requests can sometimes be resolved faster. Prescribers should document the following in the PA submission: confirmed HSDD diagnosis, absence of depression as the primary cause of low desire, current medication list (to confirm no prohibited CYP3A4 interactions), and attestation that the patient has been counseled about the alcohol restriction.

Michigan Medicaid managed care plans, including Molina Healthcare of Michigan, Blue Cross Complete of Michigan, and McLaren Health Plan, each administer PA decisions under state guidelines. Each plan may have a slightly different form, but the clinical threshold is the same.

Private Insurance Coverage for Addyi in Michigan

Private insurance coverage for Addyi in Michigan is inconsistent. Some plans place it on specialty tier 4 or tier 5, generating copays of $100 to $300 per month even after plan benefits apply. Others exclude it from the formulary entirely, classifying HSDD treatments as lifestyle drugs not subject to coverage mandates [6].

The Affordable Care Act requires coverage of FDA-approved contraceptives but does not mandate coverage of HSDD treatments, leaving plan sponsors broad discretion [7]. As a result, patients with employer-sponsored Blue Cross Blue Shield of Michigan plans, Priority Health plans, or HAP (Health Alliance Plan) coverage may find their benefit design varies significantly by employer group contract. Patients should call the member services number on their insurance card and ask specifically: "Is NDC 50974-0230-30 covered on my formulary and at what tier?"

If Addyi is excluded from a plan's formulary, physicians can submit a formulary exception request supported by clinical documentation. Exception approvals are not guaranteed but succeed in a meaningful portion of cases when the prescriber documents prior treatment attempts for HSDD symptoms, including psychological therapy and relationship counseling.

The Sprout Pharmaceuticals Savings Card: How It Works in Michigan

Sprout Pharmaceuticals offers a manufacturer copay savings card for commercially insured patients who are not enrolled in a federal or state government health program (including Medicaid or Medicare). In Michigan, eligible patients may pay as little as $0 per month for Addyi through this program, subject to a monthly cap that Sprout sets and adjusts annually [8].

The savings card does not apply to Michigan Medicaid patients, Medicare Part D patients, or uninsured patients paying full cash price. Enrollment is done online at the Addyi manufacturer website, and a card or enrollment code is issued that the dispensing pharmacy applies at the point of sale. Pharmacies that are ADDYI REMS-certified are the only dispensing locations that can apply the card.

A few practical notes for Michigan patients using the savings card. First, the pharmacy must be REMS-certified, which means not every Michigan retail pharmacy can dispense Addyi at all. Second, the card covers the patient's copay or coinsurance, not the underlying list price billed to the insurer. Third, some Michigan plans with accumulator adjustment programs claw back the dollar amount covered by the manufacturer card from the patient's deductible accumulation, effectively eliminating the financial benefit over the course of the plan year [9]. Patients should confirm with their plan whether an accumulator or maximizer program applies to specialty drug copay cards.

Compounded Flibanserin in Michigan: Legality and Cost

Compounded flibanserin is legally available in Michigan when dispensed by a licensed 503A pharmacy (a traditional compounding pharmacy operating under state licensure and USP standards) [10]. The FDA classifies flibanserin as a commercially available drug with an approved application; this status typically restricts 503B outsourcing facilities from compounding it, but 503A pharmacies may compound it for individual patients with a valid prescription when a prescriber documents a specific clinical need that the commercial product does not meet [10].

In practice, Michigan compounding pharmacies offer flibanserin in oral capsule or troche form at prices that may be significantly lower than the $880 brand list price. The cost at a 503A Michigan pharmacy in 2026 depends on the specific formulation, base ingredients, and dispensing overhead, but patients have reported prices ranging from roughly $60 to $200 per month, a fraction of the brand cost.

The tradeoff is that compounded flibanserin has not undergone FDA review for bioequivalence, purity, or potency, and the clinical trial evidence base was generated entirely with the brand Addyi formulation [11]. The BEGONIA trial published in the Journal of Sexual Medicine (2014, N=1,378) demonstrated a statistically significant increase in the number of satisfying sexual events (SSEs) per month versus placebo (P<0.001) using the brand formulation specifically [11]. Whether a compounded preparation produces equivalent outcomes is unknown.

For patients choosing compounded flibanserin in Michigan, the prescriber still must hold ADDYI REMS prescriber certification because the certification covers the molecule, not just the brand. Some compounding pharmacies dispute this interpretation, but the FDA's REMS program language applies to flibanserin as a substance [1]. Michigan prescribers should consult with their malpractice carrier and review FDA guidance before writing for a compounded formulation.

Telehealth Prescribing of Addyi in Michigan

Telehealth prescribing of flibanserin is legal in Michigan in 2026. Michigan passed telehealth parity legislation that permits prescribing of non-controlled substances via audio-visual telehealth visits, and flibanserin is not a controlled substance [12]. The ADDYI REMS program requires prescriber certification but does not require an in-person visit; the certification is a one-time registration completed online at the REMS program website.

A qualifying telehealth visit for Addyi in Michigan should include a structured assessment of sexual desire using a validated instrument such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS), a review of current medications (particularly CYP3A4 inhibitors such as fluconazole, clarithromycin, and grapefruit juice-related compounds that are explicitly contraindicated), a documented assessment of alcohol use, and confirmation of premenopausal status [13].

The drug's black-box warning about hypotension and syncope risk with alcohol means the prescriber must document a clear alcohol counseling discussion in the visit note. Patients who consume alcohol and cannot abstain during flibanserin use should not receive a prescription, regardless of whether the visit is in-person or telehealth [1].

HealthRX clinicians operate within Michigan's telehealth rules and hold ADDYI REMS certification, enabling them to evaluate, prescribe, and monitor flibanserin for eligible Michigan patients without requiring an in-person office visit.

Clinical Efficacy: What the Evidence Shows

Three key Phase 3 trials (BEGONIA, VIOLET, and DAISY) supported the FDA's 2015 approval of flibanserin 100 mg for HSDD in premenopausal women [11][14]. The BEGONIA trial (J Sex Med 2014, N=1,378) is the largest, showing a mean increase of 0.5 satisfying sexual events per month over placebo at 24 weeks and a statistically significant improvement in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score (P<0.001) [11].

A Cochrane systematic review of flibanserin trials concluded that the drug produces modest but statistically significant improvements in desire and reductions in distress, with the most common adverse effects being dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%) [14]. These adverse effects were dose-dependent and concentrated in the first weeks of treatment.

The FDA's prescribing label notes that the drug must be taken at bedtime to reduce the risk of hypotension, syncope, and accidental injury related to somnolence [1]. Patients should be instructed not to drive or operate heavy machinery for at least 6 hours after taking each dose, and ideally to take the dose just before sleep.

Regarding the magnitude of benefit, the FDA Medical Officer's review stated that "the treatment effect on the co-primary efficacy endpoints was statistically significant but modest," with responder analyses showing that roughly 8 to 13 additional women per 100 treated reported a meaningful improvement in desire compared to placebo [1]. Shared decision-making requires communicating this effect size honestly so patients can weigh it against cost, adherence requirements, and the alcohol restriction.

The Alcohol and Drug Interaction Warnings Every Michigan Patient Needs to Know

Flibanserin carries a black-box warning, the FDA's strongest safety notice, for hypotension and syncope when combined with alcohol [1]. The interaction is pharmacodynamic. Both flibanserin and alcohol lower blood pressure through overlapping mechanisms, and co-ingestion in clinical pharmacology studies produced orthostatic hypotension in a significant proportion of subjects within 2 hours of alcohol consumption [1].

The prescribing label and the REMS program both require that patients receive a Medication Guide explaining this restriction. Michigan dispensing pharmacies must provide this guide with each fill [1].

Separately, the following drug classes are contraindicated with flibanserin: strong and moderate CYP3A4 inhibitors (including fluconazole, ketoconazole, clarithromycin, erythromycin, grapefruit juice), and strong CYP2C19 inhibitors [1][4]. Flibanserin's plasma concentration rises sharply with CYP3A4 inhibition, amplifying the hypotension risk. Prescribers should perform a full medication reconciliation before issuing a prescription, and Michigan telehealth platforms should include automated drug interaction screening as part of the ordering workflow [13].

Women taking hormonal contraceptives should be aware that certain oral contraceptive formulations that contain enzyme-modulating compounds may affect flibanserin levels; the prescribing label recommends monitoring for adverse effects when these agents are used together [1].

REMS Program Requirements for Michigan Prescribers and Pharmacies

The ADDYI REMS program requires three-way certification: prescribers, pharmacies, and patients must each complete program-specific steps before the drug can be dispensed [1]. For Michigan prescribers, this means completing an online REMS registration, attesting to knowledge of the alcohol restriction and major drug interactions, and agreeing to counsel each patient using the approved talking points. The registration takes approximately 10 to 15 minutes and does not require renewal unless the prescriber changes practice location.

For Michigan pharmacies, REMS certification means completing the same online training, maintaining documentation of the process, and providing the FDA-approved Medication Guide with every dispensed prescription. Major Michigan retail pharmacy chains including CVS, Walgreens, and Rite Aid have certified locations, but not every individual store within a chain is necessarily certified. Patients should call ahead to confirm before dropping off a prescription.

Patients themselves must sign a Patient-Provider Agreement Form (PPAF) acknowledging the alcohol restriction and the interaction risks. This form is typically completed at the prescribing visit, whether in-person or via telehealth, and is retained in the medical record.

A Cost-Minimization Decision Path for Michigan Patients

The cheapest monthly cost for flibanserin in Michigan depends on insurance status, and the decision path below applies to 2026 based on currently available data.

Michigan Medicaid enrollee: Submit PA. If approved, cost share is minimal. If denied, pursue appeal with prescriber support letter citing ACOG guidelines [5] and BEGONIA trial efficacy data [11].

Commercially insured (non-government plan): Confirm formulary status by calling your insurer and asking for the NDC-level formulary lookup. If covered, apply the Sprout savings card to reduce copay. If your plan uses an accumulator adjustment program, calculate the net annual cost before committing to brand therapy. Check whether a formulary exception is worth pursuing if the drug is excluded.

Uninsured or savings-card-ineligible: Obtain a prescription from an ADDYI REMS-certified prescriber and take it to a licensed Michigan 503A compounding pharmacy. Confirm the pharmacy holds a Michigan Board of Pharmacy compounding license. Expect to pay $60 to $200 per month versus $880 for brand Addyi. Discuss the lack of bioequivalence data with your prescriber before making this choice.

Medicare Part D enrollee: Addyi is typically excluded from Part D formularies because Medicare Part D covers drugs for sexual dysfunction only in narrow circumstances. Compounded flibanserin from a 503A pharmacy is the most accessible option if Medicare is your only coverage, but it is paid entirely out of pocket [15].

Monitoring and Follow-Up After Starting Flibanserin in Michigan

The prescribing label recommends reassessing response at 8 weeks [1]. Patients who do not report a subjective improvement in desire or a reduction in distress related to low desire by week 8 are unlikely to benefit with continued treatment, and the drug should be discontinued. The 8-week reassessment can be conducted via a follow-up telehealth visit in Michigan, using the same validated instruments (FSFI or DSDS) administered at baseline.

Liver impairment affects flibanserin metabolism significantly. The drug is contraindicated in patients with hepatic impairment of any severity because flibanserin is extensively metabolized by the liver, and hepatic impairment increases AUC by 4.5-fold compared to normal hepatic function [1]. Michigan prescribers should obtain a hepatic function assessment if the patient has any history of liver disease, heavy alcohol use, or hepatitis.

Blood pressure should be checked at the 8-week follow-up visit, particularly in patients who also take antihypertensives, CNS depressants, or herbal supplements known to affect blood pressure, such as valerian or kava [4].

A patient who has been stable on flibanserin for 6 months and continues to report benefit can reasonably continue treatment with annual reassessment of HSDD symptoms, medication list, and alcohol use patterns.